CVS Caremark (CVS - Get Report) also comes highly recommended with 23 of the 26 analysts covering the stock at either strong buy (7) and buy (16) and the 12-month median price target of $45 implying potential upside of 9.8% from Tuesday's close at $41.01.
Gabelli analyst Jeff Jonas is bullish on CVS Caremark, which provides pharmacy benefit management services as well as operating more than 7,000 drugstores, because he believes the company has good cash flow and that the Caremark portion of the business has had an "amazing number of contract wins."
The company has consistently beaten the market's earnings expectations this year, and the shares have outperformed the broad market, gaining 18% vs. a marginal increase for the S&P 500. The stock now trades at a forward price-to-earnings multiple of 12.7X, and is finishing 2011 strong, hitting its 52-week high of $41.30 on Tuesday.CVS Caremark is scheduled to report its fiscal fourth-quarter results on Feb. 8, and the average estimate of analysts polled by Thomson Reuters is for a profit of 89 cents a share in the latest three months on revenue of $28.05 billion. TheStreet Ratings has an A grade for CVS ratring the stock as a buy with a price target of $48.96.